INTRODUCTION
Entry of human immunodeficiency virus type 1 (HIV-1) into human cells requires specific interactions between viral surface glycoprotein gp120 and two host cell membrane proteins, CD4 and a chemokine receptor, CCR5 or CXCR4, depending on the viral strain [reviewed in 1]. The CCR5 ␤ chemokine receptor is the coreceptor for macrophage-tropic (M-tropic, R5) HIV-1 strains and appears to be the major coreceptor in early stages of HIV-1 infection, independent of the transmission route [2, 3] . After several years of expansion in the host, viral quasispecies evolve to use the other major coreceptor, CXCR4, which is associated with a more virulent phenotype and accelerated CD4 ϩ T cell destruction, driving the development of AIDS [1] . CCR5-positive cells such as CD4
ϩ T lymphocytes and macrophages are critical primary targets in HIV-1 infection [1, 3] , and CCR5 surface expression levels appear to be a key parameter in disease progression [2, 4] . Other cell lineages that express CD4, CXCR4, and/or CCR5, such as microglia [1] and adipose cells [5] , have been shown or proposed to be targets of HIV-1 infection.
Several studies in HIV-1 epidemiology identified individuals, uninfected despite repeated exposure to HIV-1, as homozygous for the CCR5 allele ⌬32-CCR5. This mutation consists of an internal 32-bp deletion resulting in a frameshift, rendering a truncated protein that cannot be expressed on the cell surface [6, 7] . Further worldwide genetic studies on HIV-infected patients confirmed the strong protective potential of the homozygous ⌬32-CCR5 allele against HIV-1 infection [2] . These data indicate the role that CCR5 could play as a therapeutic target in early phases of the disease. In addition, since the natural ⌬32-CCR5 polymorphism is not associated with any known pathology [2, 8] or altered immune response [9] , CCR5 is being studied as a target for the design of new gene and conventional therapies to control HIV-1 cell entry. Several derivatives of the CCR5 ligand RANTES (CCL5) [10, 11] and low-molecular-weight compounds [12, 13] inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
Various groups have evaluated intracellular immunization approaches directed against numerous viral targets [reviewed in 14] , including Gag, Env, Tat, and Rev dominant-negative mutants; RNA decoys based on TAR and RRE sequences; or ribozymes targeted to int, tat, and vif genes. CD4 [15] , CXCR4 [16 -18] , and CCR5 [19 -26] have been explored as cellular targets for development of intracellular immunization strategies against HIV-1 infection. Recent use of siRNA against CD4 and HIV-1 p24 [27] or CCR5 [28] suggests encouraging strategies to inhibit HIV-1 infection.
To mimic the natural resistance of CCR5-defective individuals against HIV-1 infection, we designed several molecules and evaluated their ability to knock out CCR5 functionally in target cells for HIV-1. The truncated CCR5 protein encoded by the ⌬32-CCR5 allele is reported to interact with the wild type (wt) receptor and to exert transdominant inhibition of cell surface CCR5 expression [29, 30] . We constructed and assayed a set of truncated CCR5 molecules that conserve one, two, or four N-terminal transmembrane domains, to determine their capacity to act as stronger negative transdominant inhibitors for wt CCR5. We also combined them with previously reported intramolecular inhibitors and obtained an effective bifunctional molecule (RT-4TMK) able to establish significant resistance to HIV infection in human primary T cells.
RESULTS

Design and Functional Evaluation of Molecular Inhibitors of CCR5 Surface Expression
We designed several molecules to inhibit cell membrane expression of CCR5. The 4TM variant of CCR5 is analogous to the naturally occurring human mutant CCR5 protein generated by the ⌬32-CCR5 allele, reported to exert transdominant negative action over the wt CCR5 receptor [29, 30] . We constructed vectors encoding several additional truncated variants of CCR5, with one (1TM) and two (2TM) N-terminal transmembrane domains, respectively (Fig. 1A) , to explore whether the transdominant effect proposed for the 4TM variant can be enhanced by further deletions in the molecule. To increase retention of these molecules in the endoplasmic reticulum (ER), the KDEL tetrapeptide was linked to the C-terminus of each of the three molecules, generating 1TMK, 2TMK, and 4TMK constructs (Fig. 1A) .
As control inhibitors, we also included the C-C chemokine RANTES and a RANTES antagonist, RANTES 9-68 [10] (Fig. 1B) . The proteins were also fused to the KDEL signal peptide, generating the RTK and RT9-68K constructs, respectively (Fig. 1B) . Chemokines expressed in this manner, termed "intrakines," are described as being retained in the ER [19] . By ELISA, we measured extracellular concentrations of RANTES and its derivatives in transfected 293T cells and found that concentrations were much FIG. 1. Surface CCR5 expression inhibitory constructs. (A) Schematic representation of wt CCR5 receptor and structure of CCR5 truncated mutants generated for this study. 1TM, 2TM, and 4TM constructs are analogous to 1TMK, 2TMK, and 4TMK, respectively, with the difference that they lack the KDEL tetrapeptide. (B) Structure of RANTES-based constructs designed to function as intracellular CCR5 ligands. These constructs and those in (A) were cloned into the pcDNA3 vector. (C) Intrakine expression analysis in transfected 293T cells. A single cell sample was used for simultaneous evaluation of intra-and extracellular expression for each intrakine. The plot shows extracellular intrakine expression as determined by ELISA of 293T supernatants. Supernatant and cell lysates were collected simultaneously. n.d., not detectable (ELISA sensitivity 3 pg/ml). Bottom inset shows Western blot analysis of intracellular intrakine expression (30 g total protein was loaded in each well). Arrow indicates mobility (6.5 kDa) of wt RANTES.
higher than those previously described as the minimum required (K d ϭ 2 nM) to exert a physiological effect [31] (Fig. 1C) . The intrakines RTK and RT9-68K therefore cannot be considered purely intracellular inhibitors. In addition to the constructs described above, we studied a hammerhead ribozyme (RzR5-76) targeted to CCR5 mRNA [32] .
We examined the inhibitory potential of all constructs by cotransfection into 293 cells. A CCR5-expressing plasmid (pcCCR5) was cotransfected with a control plasmid (pcDNA3), under two conditions of molar excess, or with the same plasmid encoding the potential CCR5 inhibitors described above. Fig. 2A shows surface CCR5 expression inhibition produced by different truncated variants of CCR5. The most potent inhibitory effect was observed for the 4TMK construct (up to 70%), showing a modest increase in inhibitory potential compared to 4TM. The other inhibitors (1TM, 1TMK, 2TM, 2TMK) showed a remarkably lower ability to decrease CCR5 expression, although KDEL inclusion increased the inhibitory effect in all cases.
All RANTES (RT) variants exerted a significant inhibitory effect (up to 55%) on cell surface CCR5 expression (Fig. 2B) . Inhibition by the agonist (RT) was slightly higher than by the antagonist (RT9-68). Inclusion of KDEL (RTK and RT9-68K) did not significantly increase the inhibitory effect of intrakines, suggesting either that the intracellular effect of intrakines is as strong as the extracellular action of chemokines or that both types of molecules act at intra-and extracellular levels.
We also designed novel constructs containing two CCR5 inhibitory molecules (bifunctional inhibitors) intended to act synergistically, by combining two distinct surface CCR5 expression-inhibitory strategies with no need for cotransfection or cotransduction. The first construct consists of a fusion protein created by linking RAN-TES to the N-terminus of a truncated 4TMK molecule that lacks the RANTES binding domain (first 14 amino acids). The resulting construct, RT-4TMK, theoretically has two independent "CCR5-binding domains" and is efficiently retained in the ER, as its extracellular levels were undetectable by ELISA of transfected cell supernatants (not shown). The other construct, RTK-RzR5-76, encodes RTK and RzR5-76 in the same cistron, allowing a simultaneous inhibitory effect at two subcellular levels, as a ribozyme during CCR5 transcription and as an intrakine in ER during CCR5 export to the cell membrane.
Construction and Evaluation of Bicistronic Retroviral Vectors Encoding Surface CCR5 Expression Inhibitors
We selected the molecules shown in cotransfection experiments to be the most potent CCR5 inhibitors (RT, RTK, 4TMK, and RzR5-76), as well as the bifunctional constructs described above. All were cloned into the bicistronic retroviral vector pLZR-IRES/gfp [33] . We used the human MCF-7 breast carcinoma cell line for functional testing of the retroviral CCR5 inhibitory constructs; this cell line displays measurable CCR5-dependent behavior [34] . Binding of the IGF-1R to IGF-1 on MCF-7 cells induces RANTES secretion (at concentrations of approximately 10 -200 pg/ml) and transactivation of CCR5; CCR5 can then mediate chemotaxis in response to stimuli such as RANTES (at 1-10 ng/ml) or IGF-1 itself.
We performed a functional chemotaxis inhibition assay by comparing the RANTES-and IGF-1-induced, CCR5-mediated chemotactic response in MCF-7 cells retrovirally transduced with a control vector (pLZR-IRES/gfp) or the same vector encoding the CCR5 inhibitory constructs. Fig. 3A shows microphotographs of representative fields of stained MCF-7 transmigrated cells in a chemotaxis inhibition experiment. We evaluated chemotaxis inhibition by direct quantification of stained cells, comparing the numbers of MCF-7 cells that transmigrated when transduced with control or CCR5 inhibitor vector. Fig. 3B shows the quantitative results of several experiments. RT-4TMK was the most potent intracellular inhibitor, as it was the only one that inhibited CCR5-dependent chemotaxis in almost all transduced MCF-7 cells (90%). The ability of 4TMK or RzR5-76 to interfere with CCR5-mediated chemotaxis in MCF-7 cells was lower than that of the bifunctional inhibitor.
CCR5 Expression Blockade in Retrovirally Transduced Human T Cells
We evaluated the CCR5 inhibitor retroviral constructs in primary human T cells, which represent a main in vivo target for HIV-1. We developed a stimulation protocol to allow sustained, physiological CCR5 expression levels after sorting of transduced cells ( Fig. 4A ; Materials and Methods). We stimulated freshly isolated human peripheral blood lymphocytes (PBL) with immobilized anti-CD3 2 days before retroviral transduction and 5 days before cell sorting. High transduction efficiencies (50 -70%) were obtained routinely, using an m.o.i. of 1-2 particles/cell (Fig. 4B ). After sorting, we cultured the cells in IL-2-containing medium and evaluated the efficiency of the CCR5 inhibitory retroviral constructs.
We monitored CCR5 inhibitor expression in transduced lymphocytes by ELISA for RTK and by reverse transcriptase-polymerase chain reaction (RT-PCR) for the other inhibitors. RTK production was detected in supernatants of transduced PBL at physiological concentrations (Fig. 4C ). We were able to measure exogenously produced RANTES, since the anti-CD3 stimulation protocol used not only downregulates CCR5 but also abolishes endogenous RANTES production (not shown). We verified expression of other transgenes by RT-PCR; products of the predicted size were amplified for all constructs tested (Fig.  4C) .
We examined the effects of the ribozyme (RzR5-76), intrakines (RTK), negative transdominants (4TMK), and bifunctional constructs (RTK-RzR5-76 and RT-4TMK) on surface CCR5 expression by transduced lymphocytes in a two-color flow cytometric assay. Fig. 5A shows a timecourse plot of CCR5 inhibition by the constructs relative to CCR5 expression in control vector-transduced PBL, at days 2 to 7 after sorting. In clear contrast to intracellular inhibitors, the effect of RTK was strongly reduced following medium replacement (day 4 postsorting), indicating a predominance of the extracellular over the intracellular mechanism for this molecule. Bifunctional constructs show high, stable levels of surface CCR5 expression inhibition.
We compared the inhibitors further under the same kinetic conditions at a single time point, 3 days postsorting. Results were similar to those from kinetic studies (Fig.  5B) , although 4TMK was more efficient than the ribozyme (RzR5-76) in this assay. RTK showed very high inhibition of CCR5 expression. RT-4TMK was slightly more effective than 4TMK, perhaps due to increased affinity for CCR5, but less efficient than RTK, probably because its inhibitory action lacks the extracellular component. RTK-RzR5-76 did not show a synergistic ability to inhibit cell surface CCR5 expression compared to each of its components alone. 5 transduced cells/ml; n.d., not detectable (assay sensitivity 3 pg/ml). Bottom shows RT-PCR expression analysis of the other four CCR5 inhibitors. CϪ, no template; Cϩ, 1 pg of the corresponding retroviral plasmid; ϪRT, no reverse transcriptase added; ϩRT, cDNA; gfp, control retroviral vector. ␤-Actin amplification was used to normalize sample load.
Selective Inhibition of M-tropic HIV-1 Infection in Transduced Primary T Lymphocytes
We assessed the anti-HIV-1 activity of the CCR5 inhibitors in primary lymphocytes. Freshly isolated human PBL were stimulated as described (Fig. 4A) . Transduced T cells were infected at day 3 postsorting with R5 (BaL) or X4 (NL-4) HIV-1 strains, and viral production in cultures was monitored by measuring p24 levels every 2 to 3 days postinfection.
NL-4 strain replication was comparable for PBL transduced with control or inhibitor vectors (Fig. 6A , white and gray bars, scale at right), with the exception of RT-4TMK, which showed slight resistance to X4 strain infection compared to those control vector-transduced cells. This may indicate that RT-4TMK exerts a slight degree of nonspecific interference with other chemokine receptors, such as CXCR4. Fig. 6A plots average HIV-1 inhibition for each construct (black bars, scale at left), measured on the day of maximum p24 production in control vector-transduced T cells. RTK and RT-4TMK significantly inhibited HIV-1-mediated infection (65 and 46%, respectively); other constructs showed considerable variability among PBL donors (not shown). HIV-1 infection and CCR5 inhibition data (Figs. 6A and 5B) correspond to the same series of donors. Fig. 6B shows R5 strain HIV-1 replication data, measured as p24 production in transduced T cells from a representative healthy donor. With the exception of the RzR5-76 construct, p24 levels in inhibitor-transduced T cells were significantly lower than those of controls.
Comparison of plots for all CCR5 expression inhibitors tested shows that a close correlation can be inferred between surface CCR5 expression inhibition at the time of HIV-1 infection and HIV-1 infection inhibition (Figs. 5B and 6A); this correlation is represented in Fig. 6C . The results support a close direct correlation between membrane CCR5 expression levels and the ability of HIV-1 (R5) to enter target cells, as previously proposed [4, 35] .
DISCUSSION
CCR5 is the major HIV-1 coreceptor during early stages of infection [1] [2] [3] . Approximately 1-2% of the Caucasian population is homozygous for a 32-bp deletion in the CCR5 gene (⌬32-CCR5 allele); these individuals are healthy and almost completely resistant to HIV infection [6, 7] . CCR2, CCR3, GPR15, STRL33/Bonzo, and other chemokine receptors have been identified in vitro as secondary coreceptors for R5 strains, but to date only eight HIV-1-infected patients have been shown to be homozygous for the ⌬32-CCR5 allele [36] . These premises clearly delineate the genetic inhibition of cell surface CCR5 expression in CD4 ϩ cells as a promising therapeutic strategy for the majority of early phase HIV-1-infected patients.
Many researchers have developed genetic approaches to protect human cells from HIV- cellular gene that has a crucial role at the HIV-1 cell entry phase.
We compared the inhibitory effect of some candidate molecules and a chemokine (RANTES) linked to an ER retention signal sequence. Intracellular expression of intrakines has shown some promise in limiting viral entry [17, 21] . In addition, RANTES-KDEL was used to create new bifunctional molecules from its combination with the anti-CCR5 ribozyme or 4TMK variant of CCR5. The use of these modular molecules may extend the concept of combined therapy beyond the established pharmacological treatments.
We achieved a reduction in CCR5 expression levels in 293 cells cotransfected with CCR5 and CCR5 truncated mutants at ratios of 1:4 and 1:9. The most effective variant was 4TMK, in accordance with the recent mapping of the regions involved in the negative transdominant effect of ⌬32-CCR5 protein [30] .
Chemotaxis experiments in the MCF-7 cell line retrovirally transduced with the selected negative transdominant, ribozyme, or bifunctional constructs showed that all molecules examined exerted a significant inhibitory effect, comparable to control intrakines. The bifunctional molecules showed the most potent effects, as they inhibited CCR5-mediated chemotactic transmigration in nearly all the transduced cell populations.
We analyzed the effectiveness of the constructs in inhibiting HIV-1 infection in human PBL, a relevant cellular target for HIV-1. Again, all constructs examined significantly inhibited HIV-1 infection of transduced human T cells, although with varying efficiency. Apart from the control intrakines, the bifunctional construct RANTES-4TMK showed the most significant, reliable, and sustained interference with R5 strain HIV-1 infection and replication in human PBL. In addition, extracellular expression of RANTES-4TMK is not detected by ELISA; this molecule is thus not secreted and could be used safely for this type of clinical application. In contrast to previous results [29, 30] , Venkatesan et al. [37] were recently unable to confirm a transdominant effect or subcellular CCR5 colocalization for the ⌬32-CCR5 mutant. These authors nonetheless reported that a 6-to 10-fold excess of ⌬32-CCR5 produced a 30 -50% reduction in cell surface expression levels of cotransfected wt CCR5 and significant colocalization of wt and mutant CCR5 proteins in the ER of transfectants that were not treated with protein synthesis inhibitors [37] . Benkirane et al. showed HIV-1 infection inhibition in HeLa CD4 ϩ cells cotransfected with wt and mutant CCR5 at a 1:3 ratio [29] . Chelly et al. [30] also demonstrated a transdominant effect for the CCR5 ⌬32 variant, even when the wt CCR5 plasmid was in excess (5:1). In addition, fresh PBMC from ⌬32-CCR5 heterozygotes had significantly lower CCR5 levels than those from wt CCR5 homozygotes [35] . Al- though CCR5 and ⌬32-CCR5 proteins appear to colocalize in the ER of transfected cells, the precise nature of the interaction that mediates the transdominant effect mechanism is not clear.
Our goal was to evaluate the effectiveness of molecules designed to inhibit CCR5 expression, within a reliable and near-physiological cellular environment, that is, in the natural human lymphocyte target of HIV-1, stimulated to express CCR5 levels and CD4 ϩ :CD8 ϩ ratios similar to those of freshly purified PBL. In contrast to previous reports on intrakines [17, 19, 21] , we observed a significant reduction in CCR5 expression levels and HIV-1 replication, although not complete blockade. An important difference may lie in the protocols used for stimulation of the human PBL, which could drive CCR5 expression to low-to-moderate levels. Experimental conditions could also induce a decrease in the physiological CD4: CD8 ratio [38] , diminishing the overall ability to be infected by HIV-1 [39] . We also confirmed that the putative intracellular intrakines are secreted to the extracellular medium at high levels, as also observed by Engel et al. [40] . In our opinion, due to the potent proinflammatory action of chemokines, intrakines could not be safely applied in human gene therapy protocols.
Several authors have reported promising anti-HIV-1 results using CCR5-targeted molecules such as ribozymes [22,24 -26] and intracellular antibodies [23] ; however, the use of different cell models to evaluate construct efficiency renders it difficult to compare the inhibitory strategies. Our results are comparable and similar to those of Qin et al. [28] , who protected human PBL from HIV-1 infection (65% inhibition) with a lentiviral vector containing an anti-CCR5 siRNA.
We found close correlation between the ability of these constructs to inhibit CCR5 expression and HIV-1 replication. From the overall analysis of the results, we infer that there does not appear to be a CCR5 expression threshold for HIV-1 infection [39] , as was shown for CXCR4 and CD4 [41] . Our results indicate that, although cell surface CCR5 expression would have to be eliminated entirely to avoid HIV-1 entry, it is unnecessary to reach a minimum CCR5 expression threshold to limit the progression of HIV-1 infection. Recent genetic studies on HIV patient cohorts reached similar conclusions [42] , indicating that quantification of CCR5 expression density in peripheral blood CD4 ϩ T cells is a valuable prognostic tool for predicting patient evolution on a treatment regime.
It must be considered that blocking R5 strain entry is a potential selective pressure that could drive HIV-1 evolution to usage of CXCR4 as entry coreceptor. HIV-1 quasispecies have been shown to evolve through compensating env mutations in response to CCR5 antagonists (RANTES analogs or small molecule inhibitors) [43, 44] . Nonetheless, the selective pressure exerted by receptor antagonists, by blocking or modifying the surface of the receptor involved in env interaction, differs from that imposed by the genetic strategies described here for CCR5 expression blockade, as there is no template that would support env evolution.
The safety and feasibility of T cell reconstitution in HIV-1-infected individuals have been clearly established using autologous activated CD4 ϩ T cells. The genetic approach reported here, alone or in combination with CXCR4-targeted strategies, could thus be of additional benefit to nonsymptomatic untreated or HAART-treated HIV-1-infected patients.
MATERIALS AND METHODS
Generation of mutant RANTES and RANTES intrakine expression constructs. Constructs for intracellular expression of RANTES (RT) and a RANTES antagonist (RT 9-68) were developed as controls. Human RANTES cDNA was amplified by PCR from a pGEM-RANTES plasmid (kindly provided by Dr. T. J. Schall) using the primers RTF 5Ј-TTCGGATCCGCCACCATGAAGGTCTC-CGCGGCAGCC-3Ј and RTR 5Ј-AGTGTCGACT TAACTCATCTCCAAAGAGT-TGAT-3Ј. RANTES-KDEL (RTK) was amplified using primers RTF and RTKR 5Ј-TTAGAGCTCGTCCTTGCTCATCTCCAAAGAGTT-3Ј. The RT 9-68 antagonist was cloned in two steps. Two overlapping fragments were PCR-amplified from RANTES cDNA using primers RTF and RTspR 5Ј-GTAGGCAAAGCAG-CAGGGGGCAGATGCAGGAGCGCAG-3Ј to amplify the signal peptide and RT 9-68F 5Ј-CCCTGCTGCTTTGCCTACAT-3Ј and RTR to amplify a fragment that encodes a truncated RANTES protein. The purified PCR products were assembled by another PCR using primers RTF and RTR or RTKR to generate RANTES 9-68 and RANTES 9-68KDEL (RT 9-68K) products, respectively. The four PCR products were subcloned into pCR-Blunt vector (Invitrogen, Carlsbad, CA) and sequenced. These constructs were EcoRI digested and cloned into pcDNA3 vector (Invitrogen) to generate the constructs pcRT, pcRTK, pcRT9-68, and pcRT9-68K.
Generation of CCR5 truncated variant expression constructs. Six truncated variants of the CCR5 chemokine receptor were generated by PCR amplification of human CCR5 cDNA using a common forward primer for all molecules, CCR5-S2 5Ј-CCGCCACCATGGATTATCAAGTGTCAAGCCCAA-TC-3Ј, and six different primers to generate the C-terminal truncations: CCR5/204-A 5Ј-TTAGATGTCAGTCATGCTCTTCAGCCTTTG-3Ј to amplify a single transmembrane domain CCR5 molecule (1TM), CCR5/204-KA 5Ј-TTA-GAGTTCGTCCTTGATGTCAGTCATGCTC-3Ј to make a fusion between 1TM and the ER retention signal tetrapeptide KDEL (1TMK), CCR5/303-A 5Ј-TCACATTGTATTTCCAAAGTCCCACTG-3Ј for 2TM amplification, CCR5/ 303-KA 5Ј-TCAGAGTTCGTCCTTCATTGTATTTCCAAAG-3Ј for 2TMK, ⌬CCR5-A 5Ј-TTAGTATGGAAAATGAGAGCTGCAGGTGTAATG-3Ј for 4TM, and ⌬CCR5-KA 5Ј-TTAGAGTTCGTCCTTGTATGGAAAATGAG AGC-3Ј for 4TMK. The six PCR products were subcloned into pCR-Blunt vector, sequenced, EcoRI digested, and cloned into the same restriction site in a pcDNA3 vector to generate the constructs pc1TM, pc1TMK, pc2TM, pc2TMK, pc4TM, and pc4TMK.
Generation of bifunctional CCR5 inhibitors. pcRT was PCR amplified using primers RTF and RT-LK-R 5Ј-AGTGAATTCAGATCCGCCACCTC-CGCTCATCTCCAAAGAGTTGAT-3Ј to generate a RANTES molecule with a C-terminal linker (RT-LK). pc4TMK was amplified using primers RT/ CCR5-S 5Ј-CCCGAATTCGTGAAGCAAATCGCAGCCCGC-3Ј and ⌬CCR5-KA. RT-LK and the PCR product from pc4TMK were subsequently cloned together into the BamHI/EcoRI and EcoRI sites of pcDNA3, respectively, to generate the pcRT4TMK construct. RTK and the ribozyme RzR5-76 [32] were cloned together into the pcDNA3 vector using BamHI/EcoRI and EcoRI/XhoI restriction sites, respectively, to generate the pcRTKRzR5-76 construct.
Retroviral constructs. DNA fragments encoding RzR5-76, RT, RTK, 4TMK, RT4TMK, and RTKRzR5-76 sequences were cloned into the BamHI/XhoI sites of the pLZR-IRES/gfp retroviral vector [33] to generate the pLZR-RzR5-ARTICLE doi:10.1016/S1525-0016(03)00202-8 76-IRES/gfp, pLZR-RT-IRES/gfp, pLZR-RTK-IRES/gfp, pLZR-4TMK-IRES/gfp, pLZR-RT4TMK-IRES/gfp, and pLZR-RTKRzR5-76-IRES/gfp vectors, respectively.
Cell lines and culture. HEK 293 and 293T cell lines were kindly provided by Dr. R. Delgado. HeLa cells were obtained from the ATCC (Manassas, VA). HEK 293, 293T and HeLa cells were cultured in DMEM (Bio-Whittaker, Walkersville, MD) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Gaithersburg, MD), 50 g/ml gentamicin, and 2 mM L-glutamine (both from Bio-Whittaker). MCF-7 cells were maintained in MEM (Gibco BRL) containing 10% FBS, 50 g/ml gentamicin, 2 mM L-glutamine, and nonessential amino acids (Bio-Whittaker).
Cotransfection experiments. A full-length CCR5 cDNA clone was subcloned into the XhoI/XbaI sites of the eukaryotic expression vector pcDNA3.1/Hygro (Invitrogen) generating the pcCCR5 plasmid. HEK 293 cells were plated (2 ϫ 10 5 cells/well) in 12-well plates (Nunc, Denmark) and then cotransfected with pcCCR5 (100 ng) and different amounts of the pcDNA3 constructs encoding the potential CCR5 inhibitors described above. pcDNA3 was added to all cotransfection experiments as a carrier plasmid to a total DNA amount of 2.1 g. Transfections were performed using Lipofectamine Plus (Gibco BRL) according to the manufacturer's instructions. Surface CCR5 expression on transfected HEK 293 cells was monitored by flow cytometry 24 h posttransfection, using a polyclonal serum (s223; kindly provided by Drs. M. Mellado and J. M. Rodríguez Frade, DIO, CNB-CSIC) or PE-conjugated monoclonal anti-CCR5 antibody (clone 2D7; Pharmingen, San Diego, CA). s223 serum was developed with a fluorescein-labeled anti-rabbit Ig antibody (Amersham, Buckinghamshire, UK) and cells were analyzed in a flow cytometer (Epics XL; Coulter, Miami, FL). The percentage inhibition of CCR5 expression was calculated as % inhibition ϭ (1 Ϫ ((RFU Ϫ RFU control )/(RFU CCR5 Ϫ RFU control ))) ϫ 100, where RFU is mean relative fluorescence units of cells cotransfected with pcCCR5 and inhibitor plasmid, RFU CCR5 is mean RFU of cells transfected with pcCCR5 alone, and RFU control is mean RFU of pcDNA3-transfected cells.
Purification of human peripheral blood mononuclear cells and in vitro activation of human T lymphocytes. Peripheral blood mononuclear cells were obtained from fresh buffy coats from normal donors by Ficoll-Paque separation (Pharmacia, Uppsala, Sweden) and cultured in RPMI 1640 with 20% FBS, gentamicin (50 g/ml), L-glutamine (2 mM), 10 mM Hepes (Bio-Whittaker), and sodium pyruvate. Human T lymphocytes (2 ϫ 10 6 /2 ml/well) were activated in 24-well plates precoated with anti-CD3 mAb (UCHT1; Pharmingen; 10 g/ml, 4 h, 37°C). Where indicated, recombinant human IL-2 (PeproTech, Rocky Hill, NJ) was used at 50 IU/ml. Retroviral supernatant production and titration. High-titer retroviral supernatants were obtained essentially as described [33] . To titrate retroviral vectors, supernatants were diluted 1:200 in DMEM supplemented with 10% heat-inactivated FBS containing 8 g/ml Polybrene (Sigma), added to HeLa cells, and incubated (8 h, 37°C). EGFP-expressing transduced cells were quantified 4 days posttransduction by direct fluorescence in an EPICS XL-MCL cytometer (Coulter) and the titer (transducing units/ ml) was measured as (% positive cells ϫ number of cells at time of infection/100) ϫ dilution factor.
Retroviral transduction of MCF-7 cells and human T lymphocytes and FACS purification of transduced cells. MCF-7 cells (2.5 ϫ 10
5 ) were plated 48 h prior to retroviral transduction with 1 ml of fresh retroviral supernatant with 8 g/ml Polybrene (8 h, 37°C). Human T lymphocytes were activated with immobilized anti-CD3 mAb for 2.5 days prior to transduction. Virus transduction was performed with 1 ml of virus supernatant/ 4 -8 ϫ 10 6 cells in the presence of 8 g/ml Polybrene. Virus/cell mixtures were centrifuged (1000g, 1 h, 37°C), after which cells were resuspended in RPMI 1640 containing 20% FBS, 10 mM Hepes, 2 mM L-glutamine, 50 g/ml gentamicin and incubated for 5 additional days in contact with immobilized anti-CD3 mAb before marker and/or transgene expression analysis and FACS purification. Transduced (GFP ϩ ) T cells were sorted using an Epics Altra HSS (Beckman-Coulter) and cultured in complete RPMI medium supplemented with rhIL-2 (50 IU/ml).
Analysis of transgene expression. Expression of secreted RANTES and derived intrakines was analyzed using an ELISA detection kit for human RANTES (Cytoscreen; BioSource, Camarillo, CA) according to the manufacturer's instructions. Intracellular expression of RANTES and RANTESbased intrakines was analyzed by Western blot using a biotinylated antihRANTES mAb (R&D Systems, Minneapolis, MN), followed by peroxidaseconjugated streptavidin (Sigma).
Expression of ribozyme, 4TMK, and bifunctional inhibitors (RTKRzR5-76 and RT-4TMK) in transduced PBL was analyzed by RT-PCR using specific pairs of primers for each inhibitor; PCR products were analyzed by agarose gel electrophoresis.
Chemotaxis assay. MCF-7 cells (10 5 ), transduced with CCR5 inhibitors or pLZR-IRES/gfp as control, were suspended in 100 l MEM-0.1% bovine serum albumin (BSA) and added to the top chamber of a 6.5-mm-diameter, 8-m-pore polycarbonate Transwell (Costar, Cambridge, MA). Transwell membranes were coated with 1 g/ml vitronectin (Collaborative Biomedical Products, Bedford, MA; 4°C, overnight). Human IGF-1 (5 ng/ml; PeproTech) and human RANTES (10 ng/ml; R&D Systems) were diluted with MEM-BSA, added to the lower chamber (600 l/well), and incubated (37°C, 8 h). Cells that transmigrated were stained and counted in random microscopic fields.
HIV-1 infection and p24 determination in transduced PBL. Three days after sorting, human PBL in RPMI medium supplemented with 20% FBS and rhIL-2 (50 IU/ml) were infected with R5 (BaL) or X4 (NL-4) HIV-1 viruses (5 ng p24/10 6 cells), incubated (4 h, 37°C), washed once, and resuspended in medium. HIV-1 replication was evaluated by measuring supernatant p24 concentrations (HIV-1 p24 antigen assay; Coulter).
